Conversion from sustained-release to immediate-release bupropion: Patient tolerability and economic impact

Pharmacotherapy

Volumn 25, Issue 4, 2005, Pages 520-525

  Mayo, Janet L ^a   Cahill, Georgette M ^a   Lott, Rex S ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Bupropion; Conversion; Economics; Immediate release; Sustained release; Tolerability

Indexed keywords

AMFEBUTAMONE;

ADULT; AGED; AGITATION; ANXIETY DISORDER; DOSE RESPONSE; DRUG COST; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; REVIEW; SEIZURE; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; THORAX PAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; DELAYED-ACTION PREPARATIONS; DRUG COSTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 16344384205     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.4.520.61030     Document Type: Review

References (16)

1. Nieuwstraten CE, Dolovich LR. Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression. Ann Pharmacother 2001;35:1608-13.
2. Davidson JRT, Connor KM. Bupropion sustained release: a therapeutic overview. J Clin Psychiatry 1998;59(suppl 4):25-31.
3. Settle EC. Bupropion sustained release: side effect profile. J Clin Psychiatry. 1998;59(suppl 4):32-6.
4. Fleet JVW, Manberg PJ, Miller LL, et al. Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry 1983;44(5 pt 2):191-6.
5. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999;11:205-15.
6. Coleman CC, King BE, Bolden-Watson C, et al. A placebo controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001;23:1040-58.
7. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-30.
8. Guzey C, Norstrom A, Spigset O. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 2002;24:436-7.
9. Kennedy SH, McCann SM, Masellis M, et al. Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry 2002;63:181-6.
10. Shad MU, Preskorn SH. A possible bupropion and imipramine interaction. J Clin Psychopharmacol 1997;17:118-19.
11. Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989;50:256-61.
12. Peck AW, Stern WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressants and bupropion. J Clin Psychiatry 1983;44(5 pt 2):197-201.
13. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991;52:450-6.
14. Dunner DL, Zisook S, Billow AA, Batey SR, Johnston JA, Ascher JA. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998;59:366-73.
15. GlaxoSmithKline. Wellbutrin (bupropion) package insert. Research Triangle Park, NC; 2000.
16. Sweet RA, Pollock BG, Kirshner M, Wright B, Altieri LP, DeVane CL. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995;35:876-84.